中国生物医药企业泰邦生物集团近日从美国纳斯达克主板退市，完成私有化交易，交易对价为47.6亿美元。瑞生国际律师事务所为买方团成员中信资本提供法律意见。

泰邦生物集团公司成立于2002年，并于2009年在纳斯达克上市，是中国领先的综合性血液制品和生物医药企业，其核心业务包括血液制品和生物制品的研发、生产和销售。

瑞生团队由香港办事处合伙人孙秋宁律师牵头领导，香港办事处合伙人苏国瑞、美国办事处Bradley Faris、Alex Cohen、Paul Dudek、Joel Trotter、Nick Benson提供咨询。

Latham & Watkins advises buyer in China Biologic Products’s $4.76bln privatisation

Latham & Watkins advised CITIC Capital, one of the buyers, on blood products manufacturer China Biologic Products’ $4.76 billion privatisation deal. 

Established in 2002, China Biologic Products became listed in Nasdaq in 2009. The company focuses on research, manufacturing and selling of blood products and biological products.

The Latham team was led by Hong Kong-based partner Frank Sun, supported by Hong Kong-based partner Benjamin Su and U.S.-based partners Bradley Faris, Alex Cohen, Paul Dudek, Joel Trotter and Nick Benson.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.